Skip to search formSkip to main contentSkip to account menu

response to hydroxyurea

Known as: response to HU 
Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Hydroxyurea is FDA‐approved and now increasingly used for children with sickle cell anemia (SCA), but dosing strategies… 
2019
2019
β‐Thalassemia is a genetic disorder caused by defects in the β‐globin gene resulting in the absence or reduced synthesis of adult… 
2017
2017
Objective: To evaluate the possible relationship between hydroxyurea (HU) response and some single-nucleotide polymorphism (SNP… 
2016
2016
β‐Thalassemia is the most common hereditary disorder characterized by reduced production of β‐globin chains of hemoglobin A (HbA… 
2015
2015
Introduction: Thalassemias are a group of haematological disorders due to quantitative defect of globin chain. Patients require… 
2014
2014
Hydroxyurea has proven efficacy in children and adults with sickle cell anemia (SCA), but with considerable inter-individual… 
2014
2014
Anaplastic meningiomas are rare and aggressive tumors with a high propensity for local recurrence. Surgical resection and… 
2012
2012
Abstract 241 Although they ostensibly have a monogenetic disease, individuals with sickle cell anemia exhibit wide variability in… 
2004
2004
Hydroxyurea (HU) is an effective treatment for most patients with symptomatic sickle cell anemia, yet the fetal hemoglobin (HbF… 
Highly Cited
1997
Highly Cited
1997
Hydroxyurea (HU) can increase fetal hemoglobin (HbF) in sickle cell anemia (HbSS). To identify determinants of the HbF response…